Research News

Scientists Say Cancer Should be Classified by Genetic and Molecular Type

(August 21, 2014) A research network in the US proposes that cancer should be classified according to genetic and molecular features rather than by the type of tissue in which the tumor arises. While more work is needed to confirm and build on the findings, the scientists say such a system would be better... 

Drug Combination Impacts Outcomes in Ovarian Cancer Patients without BRCA Mutations

Ron Buckanovich, MD, PhD BRCA mutations in ovarian cancer are a double-edged sword.  While BRCA gene mutation carriers have a significantly higher risk of developing ovarian cancer, BRCA gene mutation in tumors is associated with a significant increase in patient survival.  Scientists believe that... 

Epigenetic Targeting of Ovarian Cancer Stem Cells

(July 29, 2014)   OCRF-funded research published earlier this month provides the first proof of principle that epigenomic strategies efficiently target ovarian cancer stem cells, which are key for treatment resistance and the major factor in therapy failures.  OCRF grantees Kenneth Nephew, PhD and... 

Most High Risk Women Aren’t Aware of Ovarian Cancer Risk

(July 28, 2014) Research published last week in Behavioral Medicine suggests that most high-risk women (>75%) do not know their risk for ovarian cancer. Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated risk for ovarian cancer. To understand what percentage... 

OCRF Research Sheds New Light on Ovarian Cancer Metastasis

(July 21, 2014) According to research funded in part by OCRF, circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs. This new finding, supported in part by an OCRF Program Project Development... 

OCRF Research Shows ARID1A is Tumor Suppressor Gene

Bin Guan, PhD (July 8, 2014) Frequent mutations in the ARID1A gene have been previously discovered in ovarian endometrioid and clear-cell cancers.  Now research supported by OCRF has provided direct evidence that it is an authentic tumor suppressor gene using a mouse model.  OCRF Ann Schreiber Mentored... 

Q&A with OCRF Grantee John Weroha, MD, PhD

Q&A with John Weroha, MD, PhD 2014 Liz Tilberis Early Career Award Mayo Clinic               Were you always in interested in science?  By the time I was in high school I knew I wanted to have a career in biology, but I think my interest actually started earlier. ... 

No Link Between Fertility Drugs and Breast, Ovarian and Uterine Cancers

(July 1, 2014)  There is “little evidence” that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a significant 30-year follow-up study. However,... 

Palliative Care at Time of Cancer Diagnosis Improves Survival

(June 25, 2014) Research presented at the annual meeting of the American Society of Clinical Oncology earlier this month suggests that palliative care delivered at the time of cancer diagnosis improves survival. A randomized trial of palliative oncology care in 207 patients with advanced cancer and their... 

Gemcitabine, Carboplatin, and Bevacizumab Extend PFS

(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian, peritoneal, or tubal cancer. The results, which were published...